Towards sustained human platelet production for therapeutic use
Editorial Commentary

Towards sustained human platelet production for therapeutic use

Suzanne M. Watt1,2,3, Irene Roberts1,4,5

1Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; 2Adelaide Medical School, Faculty of Health and Medical Sciences, University of Adelaide, North Terrace, Adelaide, SA, Australia; 3Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia; 4MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford, UK; 5Department of Paediatrics, University of Oxford, Children’s Hospital, John Radcliffe Hospital, Oxford, UK

Correspondence to: Professor Suzanne M. Watt. PhD, FRCPath. Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Level 4, Academic Block, John Radcliffe Hospital, Headington, Oxford, OX3 9BQ, UK. Email: suzanne.watt@ndcls.ox.ac.uk.

Comment on: Patel A, Clementelli CM, Jarocha D, et al. Pre-clinical development of a cryopreservable megakaryocytic cell product capable of sustained platelet production in mice. Transfusion 2019;59:3698-713.


Received: 01 December 2020; Accepted: 15 December 2020; Published: 30 September 2021.

doi: 10.21037/aob-20-82


Platelet concentrates are transfused for life-saving prophylactic or therapeutic purposes. These include treatment for those thrombocytopenic patients with acute or chronic blood loss, or those undergoing hematopoietic stem cell (HSC) or organ transplantation (1). In 2017, European blood banks issued over 2.9 million platelet concentrates, of which just over 2.28 million were transfused into 317,898 recipients (2). More recent estimates [although these figures are affected by and evolving during the current 2020 SARS-CoV2 pandemic (3)] indicate that over 2 million platelet concentrates (around 7,000 per day) are administered per annum to patients in the USA alone (4,5).

Although guidelines have been developed for platelet transfusions (1,5,6), and revised recently in the light of a potential scarcity of platelets during the SARS-CoV2 pandemic (3), controversies still exist as to best practice. In less challenging times, one such controversy relates to defining or developing the best platelet product for transfusion. While such platelets are generally sourced from healthy blood donors by apheresis or after isolation and pooling from whole blood (1), they possess a short shelf-life (5–7 days at room temperature), have restrictive storage conditions, rely on donor availability, are susceptible to pathogen contamination, and can lead to allo-immunisation to HLA Class I antigens (1,3,5).

The prospect that platelet donations may not meet future demands has spurred on research to generate platelets from alternative sources. These include the production of megakaryocytes and platelets from a variety of stem and progenitor cells ex vivo and the development of technologies to manufacture artificial platelets (7-9). Needless to say, platelets once generated ex vivo from stem and progenitor cells would undoubtedly face similar, or possibly even further, limitations related to shelf-life and storage conditions as those sourced directly from donors. However, advantages cited include a lack of reliance on immediate blood donor availability, reduction in the potential risk of pathogen (e.g., viral or variant Creutzfeldt-Jakob disease) transmission, and the potential to reduce their immunogenicity through, for example, genetic modification of the originating stem and progenitor cells (7,8).

A number of stem cell studies have concentrated on the use of ES (embryonic stem) or iPS (induced pluripotent stem) cells or immortalised cell lines with megakaryocytic potential for sustained platelet production, incorporating such techniques as forward programing to enhance megakaryocyte and platelet production (7,8). Safety concerns include the propensity for tumor formation through cross-contamination of the platelet products by the originating lines (7,8). An alternative approach is to manufacture and amplify megakaryocytes and their precursors ex vivo after sourcing hematopoietic stem and progenitor cells (HSPCs) from healthy human donors prior to infusion into patients, with platelet production then proceeding in vivo. Indeed, modelling studies in murine or non-human primate models indicate that megakaryocytes derived from peripheral blood (PB) or umbilical cord blood (UCB) can generate platelets in vivo (7,10-12). Furthermore, phase I clinical trials suggest that human UCB or autologous PB-derived megakaryocytes infused into patients are well tolerated (13-15). Keeping this in mind, Patel et al. (16) have recently taken an interesting approach, with a focus on developing a large scale, cryopreservable Good Manufacturing Practice (cGMP) cell product of megakaryocytes at different maturation stages, derived from human CD34+ donor UCB cells. The ultimate aim is that, once transplanted, these cells would allow the extended release of platelets within human in vivo microenvironments, via processes known to be more efficient than the ex vivo production of platelets, while overcoming other limitations associated with the generation ex vivo of human platelets from immortalized or other cell lines (7,8).

In their article “Pre-clinical development of a cryopreservable megakaryocytic cell product capable of sustained platelet production in mice”, Patel et al. (16) cultured human UCB CD34+ cells for 7 days in stem cell factor (SCF) and thrombopoietin (TPO), followed by 3 days in TPO alone. They then functionally assessed the cultured megakaryocytes before and after cryopreservation in the cGMP-grade CS10 cryoprotectant. Assessments included (I) in vitro production of megakaryocytes and their precursors, (II) hematological engraftment and PB platelet recovery in vivo in NSG mice pre-treated with human TPO (a single 0.3 µg i.p. injection), and (III) functional characterization (activation and incorporation into thrombi) of human platelets produced over an 8-week period. Accordingly, as proof of concept, Patel and colleagues isolated and expanded 5-donor cryopreserved clinical-grade UCB units ex vivo (16). From whole clinical grade UCB units, they recovered 2.3×106 CD34+ cells (median; range, 1.5–4.3×106) with a CD34+ purity of 81.2–95.3%, of which 0.3% (range, 0.2–2.8%) were CD41+. This equated to 0.94×104 (median; range, 0.8–5×104) CD41+ cells. Using a minimal cytokine combination of TPO with or without SCF for 10 days, they demonstrated enhanced ex vivo expansion of human megakaryocyte subsets. Commencing with 2.3×106 (median; range, 1.5–4.3×106) human UCB CD34+ cells, 30×106 (range, 21–34×106) CD41+CD42b+ mature megakaryocytes and 33×106 (range, 20–47×106) total CD41+ megakaryocytes were generated, making up over 50% of the expanded TNC. On average, 1.5×106 CFU-MK colonies were present in the expanded UCB units. Patel et al. (16) calculated that this would equate to a median dose for in vivo transplantation of 4.1×105 (range, 2.4–5.3×105) CD41+ cells/kg body weight for an 80-kg patient. Proceeding with transplantation of ~1.5×106 CD41+ human cells into sublethally irradiated female NSG mice, by week 1 they detected human platelets, which peaked by week 4 and then remained constant to at least week 6 post-transplant.

An important issue addressed by Patel et al. (16) was comparison of platelets derived from fresh versus cryopreserved expanded human megakaryocyte products. Comparisons were also made with donor platelets and unexpanded human CD34+ HSPCs. Notably, cryopreservation and thawing significantly reduced the recovery of viable TNC (to 66%±9%) from the expanded megakaryocyte product. This was accompanied by a transient delay in the week 2 post-transplant human platelet production in NSG mice for the cryopreserved and thawed megakaryocyte product as opposed to the fresh megakaryocyte product, but, from 3 to 8 weeks’ post-transplant, human platelet production recovered and was similar to that observed for the freshly expanded product. This extended human platelet production in NSG mice in vivo was in contrast to the short survival of human donor platelets, which were detected at 1 hour, but had declined by day 5 post-infusion, and the delayed reconstitution with unexpanded CD34+ cells (16). Platelet activation and thrombus formation of the in vivo human platelets were similar whether the platelets originated from the cryopreserved and thawed or the freshly expanded megakaryocyte products. Post-transplant, human CD34+ and CD41+ cells were detected in low numbers in both the bone marrow and lung, the proposed sites for platelet production, as well as the spleen.

This protocol raises several interesting points. First, is it possible, given the limited cell content of human UCB units, to reduce cell loss during the cGMP manufacturing process; secondly, is there a consensus about the best factor combinations to stimulate optimal megakaryocyte generation and hence their production from donor derived HSPCs ex vivo and does this differ according to human CD34+ cell source; and thirdly, what are the safety, efficacy and potency criteria for cGMP-grade CD41+ cell transplantation in patients of differing ages and with differing disorders?

Standardizing cGMP protocols is extremely time consuming and not easy to achieve. However, the magnetic bead separation technology applied by Patel et al. (16) for isolating human UCB CD34+ HSPCs is relatively rapid and simple to use, provides good to high purity, viability and reasonable recovery rates, and is a standardized cGMP compliant procedure, with results essentially consistent with earlier studies (17). There will undoubtedly be cell losses on thawing the clinical grade banked UCB units, as well as some diminution in CD34+ cell recovery after magnetic bead enrichment when starting with cryopreserved rather than freshly sourced UCB units (17). Although this information would be useful given the inherent variability of TNC content in UCB units, these losses cannot easily be assessed in the studies presented by Patel et al. (16), but will nevertheless have impacted on the numbers of megakaryocytic lineage cells that could be generated ex vivo. Additional cell loss during the second cryopreservation (i.e., of the expanded product), was observed and, although not statistically different from freshly expanded cells, may impact to some extent on potential megakaryocyte and platelet yield. Maximizing yield at every step of the process of in vivo megakaryocyte production is likely to be extremely important given the modest numbers of human platelets (103–104/µL Of mouse PB) detectable in the circulation after infusion of the ex vivo expanded products. Furthermore, it is not yet clear how long transfused CD41+ cells will persist and will continue to generate platelets. In part, this reflects uncertainties about the nature of the cells captured within the CD41+ population as this will include both megakaryocytes, their antecedent progenitors and possibly CD41+ ‘megakaryocyte-biased’ HSC, as discussed below.

With regard to the cytokines available for the megakaryocyte expansion, Patel et al. (16) chose a combination of SCF and TPO. Both are early-acting factors for human HSCs, with TPO also capable on its own of promoting the differentiation of CD41+ cells from CD34+ HSPCs (11,18). Recent studies in adult mice suggest that 30% of HSCs are megakaryocyte-biased and that these generate 50–60% of all megakaryocyte progeny in vivo (19). Whether this is the case for human HSCs or their immediate downstream progeny MPP (myeloid-primed progenitors) has not as yet been firmly established, although Psaila et al. (20) have also recently demonstrated that it is possible to isolate CD41+HSC/MPP (CD34+LinCD38CD45RACD41+) from human PB of healthy donors. While these CD41+ HSC/MPPs and their CD41- counterparts have similar myeloid potentials in vitro, the former, when cultured in the presence of SCF and TPO, show accelerated megakaryocyte differentiation (20). Interestingly, a higher fraction of cultured CD41+ HSC/MPPs expressed CD42 (the mature megakaryocyte marker) and these cells were larger and appeared earlier in the cultures than those derived from CD41 HSCs and MPPs (20). This points to the existence, in the human, of a TPO-dependent megakaryocyte-biased HSC subset, which may be the subset responsible for the megakaryocyte expansion described by Patel and colleagues (16). Whether this is the same megakaryocyte-biased HSC subset that rapidly responds with platelet production to conditions of hematological stress, infectious agents and/or inflammation is unknown and deserves further investigation (21). Other ex vivo expansion studies have used TPO alone or in combination with other cytokines (e.g., SCF, FL, IL-6, IL-11, IL-3, GM-CSF, EPO), and/or other factors including SR-1 and epigenetic modifiers, to direct or modulate megakaryocyte differentiation from human HSPCs (7,10,11,18,22,23). Whether some of these factors target particular subsets of HSCs or modulate lineage potential of HSCs to enhance megakaryocyte differentiation and to perhaps generate megakaryocytes and platelets with differing functions is not fully understood and is also worthy of further research. A further consideration is the extent to which the different culture conditions and cytokines generate myeloid and lymphoid cells, in addition to megakaryocyte lineage cells, with attendant potential risks of alloimmunization. Thus, there is still no general consensus as to the best cytokine and factor combinations for optimal generation of megakaryocytes from human UCB, PB or bone marrow CD34+ HSPCs for different clinical indications in patients.

Other questions that remain incompletely resolved in relation to translating such processes ex vivo into manufacturing strategies for clinical use include differences in megakaryopoiesis during ontogeny, the appropriate source of human HSPCs for adult versus pediatric patients, the different in vivo microenvironmental influences that impact on platelet production post-transplantation of megakaryocytes, the dose of expanded megakaryocytes that can be safely and effectively infused into patients of different ages, and whether the addition of certain factors to the ex vivo cultures creates an ‘in vitro inflammatory’ or altered environment that modulates the function and characteristics of the megakaryocytes and platelets generated (7,8,21,24,25). This may be a particular problem if large numbers of megakaryocytes lodge or engraft in the lung. The data from Patel et al. (16) are encouraging in that there was no evidence of microthrombi in the lungs of mice infused with expanded CD41+ cells and, indeed, no evidence of a hypercoagulable state which is another potential risk of transfusion of these cells.

A strength of this study by Patel and colleagues (16) is its use of donor derived megakaryocytes from human CD34+ HSPCs, which are potentially safer and less onerous to prepare than human ES, iPS, AT (adipose tissue) or immortalised cell-derived megakaryocyte products (7), also making it easier to meet cGMP and regulatory requirements. In particular, the former can be derived from pre-screened, HLA- and blood group-typed healthy donors in a shorter time, without reprograming, forward programing or immortalization with genes that may potentially promote selective cell survival or growth advantages and increase the risk of tumor formation (7,8). There is also the added advantage of over 798,500 banked, tested and typed cGMP-grade UCB donations registered with the WMDA Search and Match registry (https://statistics.wmda.info/; November 20, 2020) that are potentially accessible for clinical use. Another strength, albeit using an immunodeficient mouse model, is that it has already been demonstrated previously that co-transplanting TPO expanded human UCB CD34+ HSPCs with unmanipulated human UCB CD34+ HSPCs from a second donor results in accelerated earlier platelet recovery from the TPO-treated graft until the untreated CD34+ cell graft makes a delayed but dominant contribution to platelet engraftment over the intermediate to longer term (11). Furthermore, there were no significant adverse events reported when megakaryocytes derived from donated human CD34+ HSCs were tested by others in safety clinical trials in man (13-15). One disadvantage, depending on clinical usage, remains the limited cell numbers in UCB units. Additionally, megakaryocytes derived from human UCB CD34+ HSPCs are smaller and demonstrate lower ploidy than those derived from adult human CD34+ HSPCs (24,25). These parameters are associated with reduced and smaller, but cytoplasmically mature, platelet production in vivo. While this is thought to mostly represent cell-intrinsic behaviour, it is possible that such parameters can be modulated by microenvironmental influences, thereby enhancing platelet production (7,21-25).

In conclusion, Patel et al. (16) have taken a significant step forward in the cGMP development of megakaryocyte manufacturing from healthy human donors. There are still challenges to be met. These include determining optimal cell numbers and content of the cellular products for transplantation and ensuring safety and functional efficacy of these cellular products in vivo in human clinical trials. Furthermore, it seems inevitable that further advances in basic research will significantly increase our knowledge of human megakaryopoiesis during ontogeny and more clearly define the newer functions being attributed to HSC, megakaryocyte and platelet subsets. This will also contribute to selecting the best sources of such cells for transplantation of particular patient cohorts in defined age groups and it is hoped will eventually allow the cGMP manufacturing processes to mimic the huge blood cell production achieved under daily homeostatic conditions in vivo.


Acknowledgments

We would like to acknowledge all publications that have contributed to an improved understanding of hematopoiesis and which we have not been able to quote given reference limits.

Funding: None.


Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Annals of Blood. The article did not undergo external peer review.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/aob-20-82). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.


References

  1. Solves Alcaina P. Platelet transfusion: and update on challenges and outcomes. J Blood Med 2020;11:19-26. [Crossref] [PubMed]
  2. European Commission: Summary of the 2018 annual reporting of serious adverse reactions and events for blood and blood components. Ares (2020) 147169-10/01/2020.
  3. Stanworth SJ, New HV, Apelseth TO, et al. Effects of the COVID-19 pandemic on supply and use of blood for transfusion. Lancet Haematol 2020;7:e756-64. [Crossref] [PubMed]
  4. American Red Cross. Blood needs & blood supply. Available online https://www.redcrossblood.org/donate-blood/how-to-donate/how-blood-donations-help/blood-needs-blood-supply.html. Accessed 30/11/2020.
  5. Solves P. Platelet transfusion in real life. Ann Blood 2020;5:20-3. [Crossref]
  6. Estcourt LJ, Birchall J, Allard S, et al. British Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. Br J Haematol 2017;176:365-94. [Crossref] [PubMed]
  7. Martínez-Botía P, Acebes-Huerta A, Seghatchian J, et al. In vitro platelet production for transfusion purposes: Where are we now? Transfus Apher Sci 2020;59:102864-7. [Crossref] [PubMed]
  8. Mookerjee S, Foster HR, Waller AK, et al. In vitro-derived platelets: the challenges we will have to face to assess quality and safety. Platelets 2020;31:724-30. [Crossref] [PubMed]
  9. Girish A, Sekhon U, Sen Gupta A. Bioinspired artificial platelets for transfusion applications in traumatic hemorrhage. Transfusion 2020;60:229-31. [Crossref] [PubMed]
  10. Guan X, Qin M, Zhang Y, et al. Safety and efficacy of megakaryocytes induced from hematopoietic stem cells in murine and nonhuman primate models. Stem Cells Transl Med 2017;6:897-909. [Crossref] [PubMed]
  11. van der Garde M, van Hensbergen Y, Brand A, et al. Thrombopoietin treatment of one graft in a double cord blood transplant provides early platelet recovery while contributing to long-term engraftment in NSG mice. Stem Cells Dev 2015;24:67-76. [Crossref] [PubMed]
  12. Wang Y, Hayes V, Jarocha D, et al. Comparative analysis of human ex vivo-generated platelets vs megakaryocyte-generated platelets in mice: a cautionary tale. Blood 2015;125:3627-36. [Crossref] [PubMed]
  13. Xi J, Zhu H, Liu D, et al. Infusion of megakaryocytic progenitor products generated from cord blood hematopoietic stem/progenitor cells: results of the phase 1 study. PLoS One 2013;8:e54941-7. [Crossref] [PubMed]
  14. Bertolini F, Battaglia M, Pedrazzoli P, et al. Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. Blood 1997;89:2679-88. [Crossref] [PubMed]
  15. Decaudin D, Vantelon JM, Bourhis JH, et al. Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma. Bone Marrow Transplant 2004;34:1089-93. [Crossref] [PubMed]
  16. Patel A, Clementelli CM, Jarocha D, et al. Pre-clinical development of a cryopreservable megakaryocytic cell product capable of sustained platelet production in mice. Transfusion 2019;59:3698-713. [Crossref] [PubMed]
  17. Mata MF, Hernandez D, Rologi E, et al. A modified CD34+ hematopoietic stem and progenitor cell isolation strategy from cryopreserved human umbilical cord blood. Transfusion 2019;59:3560-9. [Crossref] [PubMed]
  18. De Bruyn C, Delforge A, Martiat P, et al. Ex vivo expansion of megakaryocyte progenitor cells: cord blood versus mobilized peripheral blood. Stem Cells Dev 2005;14:415-24. [Crossref] [PubMed]
  19. Rodriguez-Fraticelli AE, Weinreb C, Wang SW, et al. Single-cell lineage tracing unveils a role for TCF15 in haematopoiesis. Nature 2020;583:585-9. [Crossref] [PubMed]
  20. Psaila B, Wang G, Rodriguez-Meira A, et al. Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets. Mol Cell 2020;78:477-492.e8. [Crossref] [PubMed]
  21. Couldwell G, Machlus KR. Modulation of megakaryopoiesis and platelet production during inflammation. Thromb Res 2019;179:114-20. [Crossref] [PubMed]
  22. Elagib KE, Lu CH, Mosoyan G, et al. Neonatal expression of RNA-binding protein IGF2BP3 regulates the human fetal-adult megakaryocyte transition. J Clin Invest 2017;127:2365-77. [Crossref] [PubMed]
  23. Hua P, Hester J, Adigbli G, et al. The BET inhibitor CPI203 promotes ex vivo expansion of cord blood long-term repopulating HSCs and megakaryocytes. Blood 2020;136:2410-5. [Crossref] [PubMed]
  24. Davenport P, Liu ZJ, Sola-Visner M. Changes in megakaryopoiesis over ontogeny and their implications in health and disease. Platelets 2020;31:692-9. [Crossref] [PubMed]
  25. Vainchenker W, Raslova H. Megakaryocyte polyploidization: role in platelet production. Platelets 2020;31:707-16. [Crossref] [PubMed]
doi: 10.21037/aob-20-82
Cite this article as: Watt SM, Roberts I. Towards sustained human platelet production for therapeutic use. Ann Blood 2021;6:23.